43 related articles for article (PubMed ID: 8362600)
1. In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.
Jahn B; Brieger J; Fenchel K; Mitrou PS; Bergmann L
Cancer Immunol Immunother; 1994 May; 38(5):304-10. PubMed ID: 8162612
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract][Full Text] [Related]
3. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
Cancer Immunol Immunother; 1992; 35(6):401-11. PubMed ID: 1394343
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract][Full Text] [Related]
5. Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.
Acerbis G; Cleris L; Rodolfo M; Parmiani G; Formelli F
Cancer Immunol Immunother; 1992; 34(6):383-8. PubMed ID: 1563015
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Slavin S; Ackerstein A; Or R; Shapira MY; Gesundheit B; Askenasy N; Morecki S
Cancer Immunol Immunother; 2010 Oct; 59(10):1511-9. PubMed ID: 20563804
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients.
Boue F; Pastran Z; Spielmann M; Le Chevalier T; Subirana R; Sevin D; Paoletti C; Brandely M; Avril MF; Sancho-Garnier H
Cancer Immunol Immunother; 1990; 32(1):67-70. PubMed ID: 2126985
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM; Weimar W; Tank B; Dekkers-Bijma AM; Marquet RL; Lameris JS; Westbroek DL; Jeekel J
Cancer Immunol Immunother; 1986; 21(1):81-4. PubMed ID: 3632919
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract][Full Text] [Related]
10. Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.
Spicer DV; Kelley A; Herman R; Dean G; Stevenson L; Mitchell MS
Cancer Immunol Immunother; 1992; 34(6):424-6. PubMed ID: 1532923
[TBL] [Abstract][Full Text] [Related]
11. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.
Dodds MG; Frederiksen KS; Skak K; Hansen LT; Lundsgaard D; Thompson JA; Hughes SD
Cancer Immunol Immunother; 2009 Jun; 58(6):843-54. PubMed ID: 18925392
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT; Cini JK; Dexter S; DaFonseca M; Bingham J; Kuan I; Chawla SP; Polasek TM; Lickliter J; Ryan PJ
Front Immunol; 2024; 15():1362775. PubMed ID: 38487528
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of recombinant gamma interferon in patients with cancer.
Foon KA; Sherwin SA; Abrams PG; Stevenson HC; Holmes P; Maluish AE; Oldham RK; Herberman RB
Cancer Immunol Immunother; 1985; 20(3):193-7. PubMed ID: 3933818
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.
Wagstaff J; Smith D; Nelmes P; Loynds P; Crowther D
Cancer Immunol Immunother; 1987; 25(1):54-8. PubMed ID: 3109738
[TBL] [Abstract][Full Text] [Related]
15. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
Schomburg A; Kirchner H; Atzpodien J
Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
[TBL] [Abstract][Full Text] [Related]
16. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
[TBL] [Abstract][Full Text] [Related]
17. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Atzpodien J
J Cancer Res Clin Oncol; 1993; 119(12):745-55. PubMed ID: 8408187
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]